JP2019510832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510832A5 JP2019510832A5 JP2019503632A JP2019503632A JP2019510832A5 JP 2019510832 A5 JP2019510832 A5 JP 2019510832A5 JP 2019503632 A JP2019503632 A JP 2019503632A JP 2019503632 A JP2019503632 A JP 2019503632A JP 2019510832 A5 JP2019510832 A5 JP 2019510832A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- chemokine receptor
- receptor antagonist
- ccr1 chemokine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 22
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 22
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 21
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 21
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 16
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 16
- 239000012270 PD-1 inhibitor Substances 0.000 claims 15
- 239000012668 PD-1-inhibitor Substances 0.000 claims 15
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 229950002916 avelumab Drugs 0.000 claims 3
- 229960000106 biosimilars Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229940121497 sintilimab Drugs 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022092430A JP7611189B2 (ja) | 2016-04-07 | 2022-06-07 | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319689P | 2016-04-07 | 2016-04-07 | |
| US62/319,689 | 2016-04-07 | ||
| PCT/US2017/026290 WO2017176965A1 (en) | 2016-04-07 | 2017-04-06 | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092430A Division JP7611189B2 (ja) | 2016-04-07 | 2022-06-07 | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510832A JP2019510832A (ja) | 2019-04-18 |
| JP2019510832A5 true JP2019510832A5 (enExample) | 2020-05-14 |
| JP7539231B2 JP7539231B2 (ja) | 2024-08-23 |
Family
ID=59999231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503632A Active JP7539231B2 (ja) | 2016-04-07 | 2017-04-06 | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
| JP2022092430A Active JP7611189B2 (ja) | 2016-04-07 | 2022-06-07 | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092430A Active JP7611189B2 (ja) | 2016-04-07 | 2022-06-07 | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10568870B2 (enExample) |
| EP (1) | EP3439653B1 (enExample) |
| JP (2) | JP7539231B2 (enExample) |
| KR (1) | KR102370704B1 (enExample) |
| CN (1) | CN109310677A (enExample) |
| AR (1) | AR108202A1 (enExample) |
| AU (1) | AU2017246460B2 (enExample) |
| BR (1) | BR112018070361A2 (enExample) |
| DK (1) | DK3439653T3 (enExample) |
| ES (1) | ES2864148T3 (enExample) |
| IL (1) | IL261998B2 (enExample) |
| MX (1) | MX384929B (enExample) |
| PL (1) | PL3439653T3 (enExample) |
| PT (1) | PT3439653T (enExample) |
| RU (1) | RU2745195C2 (enExample) |
| SG (1) | SG11201808626WA (enExample) |
| TW (1) | TWI808938B (enExample) |
| WO (1) | WO2017176965A1 (enExample) |
| ZA (1) | ZA201806633B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| BR112018070361A2 (pt) | 2016-04-07 | 2019-01-29 | Chemocentryx Inc | redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
| KR102401963B1 (ko) | 2016-06-27 | 2022-05-25 | 케모센트릭스, 인크. | 면역조절제 화합물 |
| RU2730984C1 (ru) * | 2017-03-29 | 2020-08-26 | Сионоги Энд Ко., Лтд. | Фармацевтическая композиция для лечения злокачественного новообразования |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102670486B1 (ko) | 2017-08-08 | 2024-05-28 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
| MX2020006530A (es) | 2017-12-22 | 2020-10-15 | Codagenix Inc | Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer. |
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | INDANAMINE AS PD-L1 ANTAGONISTS |
| CA3091508A1 (en) | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
| EP3806846A1 (en) * | 2018-06-15 | 2021-04-21 | Board of Regents, The University of Texas System | Methods of treating and preventing breast cancer with s-equol |
| WO2019240872A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| EP3843711A4 (en) * | 2018-08-29 | 2022-08-03 | ChemoCentryx, Inc. | METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| JP2022501361A (ja) | 2018-09-19 | 2022-01-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用 |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| HUE067601T2 (hu) | 2018-11-14 | 2024-10-28 | Regeneron Pharma | PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére |
| MA55084A (fr) | 2019-02-28 | 2022-01-05 | Regeneron Pharma | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
| WO2020180727A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN114206338B (zh) | 2019-07-10 | 2025-12-12 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| MX2022003001A (es) * | 2019-09-11 | 2022-04-07 | Boehringer Ingelheim Io Canada Inc | Metodos para tratar el cancer mediante el uso de inhibidores del eje de pd-1 y anticuerpos anti-periostina. |
| GB201918692D0 (en) * | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
| US20230331858A1 (en) * | 2019-12-24 | 2023-10-19 | Neoleukin Therapeutics, Inc. | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| TW202207940A (zh) | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| IL298273A (en) | 2020-05-26 | 2023-01-01 | Regeneron Pharma | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
| CA3168743A1 (en) | 2020-08-26 | 2022-03-03 | Matthew G. Fury | Methods of treating cancer by administering a pd-1 inhibitor |
| WO2022051448A1 (en) | 2020-09-03 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer pain by administering a pd-1 inhibitor |
| AU2021362156A1 (en) * | 2020-10-13 | 2023-06-15 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
| AU2022242000A1 (en) | 2021-03-23 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
| AU2022314735A1 (en) | 2021-07-19 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| IL314851A (en) | 2022-02-17 | 2024-10-01 | Regeneron Pharma | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
| WO2023230220A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| WO2025080538A1 (en) | 2023-10-09 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2229617A1 (en) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE19539091A1 (de) | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| WO2002024656A1 (en) | 2000-09-22 | 2002-03-28 | Nihon Nohyaku Co., Ltd. | N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| WO2004099156A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| US7381714B2 (en) | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| DK1906965T3 (en) * | 2005-06-22 | 2015-08-03 | Chemocentryx Inc | Azaindazol compounds and methods of use thereof |
| US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| FR2887450B1 (fr) | 2005-06-23 | 2007-08-24 | Rhodia Chimie Sa | Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques |
| WO2007026834A1 (ja) | 2005-09-01 | 2007-03-08 | Kumiai Chemical Industry Co., Ltd. | ピラゾール誘導体及び農園芸用除草剤 |
| US7576218B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | 4-phenylpiperdine-pyrazole CCR1 antagonists |
| US20090252779A1 (en) | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| ES2430821T3 (es) | 2006-10-10 | 2013-11-21 | Amgen Inc. | Compuestos de N-arilpirazol para usar contra la diabetes |
| US20100113776A1 (en) | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
| US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
| WO2010030815A1 (en) | 2008-09-11 | 2010-03-18 | Chemocentryx, Inc. | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
| WO2008147815A1 (en) | 2007-05-22 | 2008-12-04 | Chemocentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP3663295A1 (en) | 2007-06-22 | 2020-06-10 | Eli Lilly And Co. | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
| PL2221298T3 (pl) | 2007-11-13 | 2014-05-30 | Taisho Pharmaceutical Co Ltd | Pochodne fenylopirazolu |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2009137338A1 (en) | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| GB0915892D0 (en) | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| JP2015512910A (ja) | 2012-03-29 | 2015-04-30 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物 |
| WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102129636B1 (ko) | 2012-05-31 | 2020-07-03 | 제넨테크, 인크. | Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법 |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JP6339573B2 (ja) * | 2012-08-27 | 2018-06-06 | ケモセントリックス，インコーポレイティド | ケモカイン受容体のアンタゴニスト |
| RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| CN104918921B (zh) | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | 二唑酰胺 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SG11201600310QA (en) * | 2013-07-16 | 2016-02-26 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| JP6586087B2 (ja) | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| SG11201601679TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| ES2675027T3 (es) | 2013-09-06 | 2018-07-05 | Aurigene Discovery Technologies Limited | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| SG11201601685TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| AU2015267051B2 (en) * | 2014-05-27 | 2022-03-17 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| CA2954508A1 (en) * | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| CA3220902A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CU20170117A7 (es) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Tech Ltd | COMPUESTOS TIADIAZOL y 1,3,4-OXADIAZOL 3-SUSTITUIDOS COMO INMUNOMODULADORES |
| SG11201706902SA (en) | 2015-03-10 | 2017-09-28 | Aurigene Discovery Tech Ltd | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| JP2018507885A (ja) | 2015-03-10 | 2018-03-22 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物 |
| CU20170116A7 (es) | 2015-03-10 | 2018-06-05 | Aurigene Discovery Tech Ltd | Compuestos cíclicos terapéuticos como inmunomoduladores |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10110466B2 (en) * | 2015-11-23 | 2018-10-23 | Tyco Electronics Subsea Communications Llc | Optical communication system with distributed wet plant manager |
| BR112018070361A2 (pt) | 2016-04-07 | 2019-01-29 | Chemocentryx Inc | redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
-
2017
- 2017-04-06 BR BR112018070361A patent/BR112018070361A2/pt not_active Application Discontinuation
- 2017-04-06 PT PT177798014T patent/PT3439653T/pt unknown
- 2017-04-06 TW TW106111608A patent/TWI808938B/zh active
- 2017-04-06 MX MX2018012132A patent/MX384929B/es unknown
- 2017-04-06 ES ES17779801T patent/ES2864148T3/es active Active
- 2017-04-06 DK DK17779801.4T patent/DK3439653T3/da active
- 2017-04-06 JP JP2019503632A patent/JP7539231B2/ja active Active
- 2017-04-06 EP EP17779801.4A patent/EP3439653B1/en active Active
- 2017-04-06 SG SG11201808626WA patent/SG11201808626WA/en unknown
- 2017-04-06 US US15/480,992 patent/US10568870B2/en active Active
- 2017-04-06 AU AU2017246460A patent/AU2017246460B2/en active Active
- 2017-04-06 IL IL261998A patent/IL261998B2/en unknown
- 2017-04-06 WO PCT/US2017/026290 patent/WO2017176965A1/en not_active Ceased
- 2017-04-06 RU RU2018138828A patent/RU2745195C2/ru active
- 2017-04-06 PL PL17779801T patent/PL3439653T3/pl unknown
- 2017-04-06 KR KR1020187032233A patent/KR102370704B1/ko active Active
- 2017-04-06 CN CN201780034790.7A patent/CN109310677A/zh active Pending
- 2017-04-07 AR ARP170100898A patent/AR108202A1/es unknown
-
2018
- 2018-10-05 ZA ZA2018/06633A patent/ZA201806633B/en unknown
-
2020
- 2020-01-14 US US16/742,139 patent/US11744822B2/en active Active
-
2022
- 2022-06-07 JP JP2022092430A patent/JP7611189B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510832A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2019503365A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2009514870A5 (enExample) | ||
| JP2019508440A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2017530984A5 (enExample) | ||
| JP2019518741A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| JP2015508103A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2016536286A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| JP2015500209A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2013528174A5 (enExample) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2015502926A5 (enExample) |